Showing 321 - 340 results of 104,129 for search '(( a fold decrease ) OR ( 5 ((step decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.43s Refine Results
  1. 321
  2. 322
  3. 323

    HRMECs treated with 3-Deazaneplanocin A (DZNep) chemical inhibitor demonstrated increased miR-200b and decreased VEGF expression. by Michael Anthony Ruiz (726055)

    Published 2015
    “…[NG = 5mM D-glucose, HG = 25mM D-glucose, NG+DMSO = 5mM D-glucose + 0.05% DMSO, HG+DMSO = 25mM D-glucose + 0.05% DMSO, NG+DZNEP = 5mM D-glucose + 5μM DZNep, HG+DZNEP = 25mM + 5μM DZNep; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to β-actin for VEGF and U6 for miR-200b, expressed as a fold change of NG].…”
  4. 324
  5. 325
  6. 326
  7. 327

    Analysis of Drugs in Whole Blood by Paper Spray Mass Spectrometry with Integrated Solid-Phase Extraction by Greta Ren (9974860)

    Published 2025
    “…The detection limits were at single digit or subng/mL levels or lower for all analytes for 70 μL blood sample, with a median decrease of 9-fold compared to paper spray without SPE.…”
  8. 328

    TUDCA decreases MPO with improved mitochondrial biogenesis, mitochondria-ER contact, and alveolar formation of HOX neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

    Published 2022
    “…<p>(<b>A</b>) The increased MPO levels in HOX neonatal lungs are decreased by TUDCA treatment (0.1±0.1-fold; n = 6, p<0.05). …”
  9. 329
  10. 330
  11. 331
  12. 332
  13. 333
  14. 334

    Pharmacodynamic Profile of CCX168 in Healthy Human Volunteers. by Pirow Bekker (392139)

    Published 2016
    “…CD11b upregulation was diminished in both blood samples from CCX168 subjects with a 10-fold decrease in C5a potency exhibited in the 12-hour samples.…”
  15. 335
  16. 336
  17. 337
  18. 338
  19. 339
  20. 340